Rethinking about Metformin: Promising Potentials

키워드

참고문헌 (68)

1. Wang Y, "Association between metformin use and disease progression in obese people with knee osteoarthritis : data from the Osteoarthritis Initiative : a prospective cohort study", Arthritis Res Ther, 21, pp.127~ (2019)
2. Cicero AF, "Metformin and its clinical use : new insights for an old drug in clinical practice", Arch Med Sci, 8, pp.907~917 (2012)
3. Bailey CJ, "Metformin : historical overview", Diabetologia, 60, pp.1566~1576 (2017)
4. Foretz M, "Metformin : update on mechanisms of action and repurposing potential", Nat Rev Endocrinol, 19, pp.460~476 (2023)
5. Holman RR, "10-year follow-up of intensive glucose control in type 2 diabetes", N Engl J Med, 359, pp.1577~1589 (2008)
6. Hirst JA, "Quantifying the effect of metformin treatment and dose on glycemic control", Diabetes Care, 35, pp.446~454 (2012)
7. Rena G, "The mechanisms of action of metformin", Diabetologia, 60, pp.1577~1585 (2017)
8. LaMoia TE, "Cellular and molecular mechanisms of metformin action", Endocr Rev, 42, pp.77~96 (2021)
9. Ma T, "Low-dose metformin targets the lysosomal AMPK pathway through PEN2", Nature, 603, pp.159~165 (2022)
10. Liu L, "Low-dose metformin and PEN2-dependent lysosomal AMPK activation : benefits outnumber side effects", Signal Transduct Target Ther, 7, pp.178~ (2022)
11. Agius L, "The metformin mechanism on gluconeogenesis and AMPK activation : the metabolite perspective", Int J Mol Sci, 21, pp.3240~ (2020)
12. Herman R, "Metformin and insulin resistance : a review of the underlying mechanisms behind changes in GLUT4-mediated glucose transport", Int J Mol Sci, 23, pp.1264~ (2022)
13. Chadt A, "Glucose transporters in adipose tissue, liver, and skeletal muscle in metabolic health and disease", Pflugers Arch, 472, pp.1273~1298 (2020)
14. Bahne E, "Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes", JCI Insight, 3, pp.e93936~ (2018)
15. Graham GG, "Clinical pharmacokinetics of metformin", Clin Pharmacokinet, 50, pp.81~98 (2011)
16. Tucker GT, "Metformin kinetics in healthy subjects and in patients with diabetes mellitus", Br J Clin Pharmacol, 12, pp.235~246 (1981)
17. Liang X, "Transporters involved in metformin pharmacokinetics and treatment response", J Pharm Sci, 106, pp.2245~2250 (2017)
18. Saiz-Rodriguez M, "Identification of transporter polymorphisms influencing metformin pharmacokinetics in healthy volunteers", J Pers Med, 13, pp.489~ (2023)
19. Peng A, "Association between organic cation transporter genetic polymorphisms and metformin response and intolerance in T2DM individuals : a systematic review and meta-analysis", Front Public Health, 11, pp.1183879~ (2023)
20. Nagai Y, "Effects of Increasing metformin dose vs adding", switching to dipeptidyl peptidase-4 inhibitors on glycemic control in patients with type 2 diabetes, 2021, pp.12, 897~911
21. Mannucci E, "Effect of metformin on glucagon-like peptide 1(GLP-1)and leptin levels in obese nondiabetic subjects", Diabetes Care, 24, pp.489~494 (2001)
22. Ilias I, "Metformin : sex", gender differences in its uses and effects-narrative review, 2022, pp.58, 430~
23. Sun ML, "Effects of food on pharmacokinetics and safety of metformin hydrochloride tablets : a meta-analysis of pharmacokinetic, bioavailability, or bioequivalence studies", Heliyon, 9, pp.e17906~ (2023)
24. Orloff J, "Safety and effectiveness of metformin in patients with reduced renal function : a systematic review", Diabetes Obes Metab, 23, pp.2035~2047 (2021)
25. Nathan DM, "Medical management of hyperglycemia in type 2 diabetes : a consensus algorithm for the initiation and adjustment of therapy : a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes", Diabetes Care, 32, pp.193~203 (2009)
26. Diabetes Prevention Program Research Group, "Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study", Diabetes Care, 35, pp.731~737 (2012)
27. Inzucchi SE, "Metformin in patients with type 2 diabetes and kidney disease : a systematic review", JAMA, 312, pp.2668~2675 (2014)
28. Hung SC, "Metformin use and mortality in patients with advanced chronic kidney disease : national, retrospective, observational, cohort study", Lancet Diabetes Endocrinol, 3, pp.605~614 (2015)
29. de Vries ST, "Sex differences in adverse drug reactions of metformin : a longitudinal survey study", Drug Saf, 43, pp.489~495 (2020)
30. de Jong L, "Time course, outcome and management of adverse drug reactions associated with metformin from patient’s perspective : a prospective, observational cohort study in the Netherlands", Eur J Clin Pharmacol, 72, pp.615~622 (2016)
31. Froldi G, "View on metformin : antidiabetic and pleiotropic effects, pharmacokinetics, side effects, and sex-related differences", Pharmaceuticals(Basel), 17, pp.478~ (2024)
32. Bonnet F, "Understanding and overcoming metformin gastrointestinal intolerance", Diabetes Obes Metab, 19, pp.473~481 (2017)
33. Bryrup T, "Metformin-induced changes of the gut microbiota in healthy young men : results of a non-blinded, one-armed intervention study", Diabetologia, 62, pp.1024~1035 (2019)
34. Forslund K, "Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota", Nature, 528, pp.262~266 (2015)
35. Seicaru EM, "Enhancing metformin effects by adding gut microbiota modulators to ameliorate the metabolic status of obese, insulin-resistant hosts", J Gastrointestin Liver Dis, 31, pp.344~354 (2022)
36. Burton JH, "Addition of a gastrointestinal microbiome modulator to metformin improves metformin tolerance and fasting glucose levels", J Diabetes Sci Technol, 9, pp.808~814 (2015)
37. Wile DJ, "Association of metformin, elevated homocysteine, and methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy", Diabetes Care, 33, pp.156~161 (2010)
38. Yang R, "Metformin treatment and risk of diabetic peripheral neuropathy in patients with type 2 diabetes mellitus in Beijing, China", Front Endocrinol(Lausanne), 14, pp.1082720~ (2023)
39. Yazidi M, "Metformin-induced vitamin B12 deficiency in patients with type 2 diabetes : a narrative review with a practical approach for screening, diagnosing, and managing vitamin B12 deficiency", Korean J Fam Med, 45, pp.189~198 (2024)
40. Hurley-Kim K, "Effect of metformin use on vitamin B12 deficiency over time(EMBER) : a real-world evidence database study", Endocr Pract, 29, pp.862~867 (2023)
41. Wee AKH, "Determinants of vitamin B12 deficiency in patients with type-2 diabetes mellitus : a primary-care retrospective cohort study", BMC Prim Care, 24, pp.102~ (2023)
42. Yoval-Sanchez B, "Effect of metformin on intact mitochondria from liver and brain : concept revisited", Eur J Pharmacol, 931, pp.175177~ (2022)
43. Foretz M, "Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1", AMPK pathway via a decrease in hepatic energy state, 2010, pp.120, 2355~2369
44. Madiraju AK, "Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase", Nature, 510, pp.542~546 (2014)
45. Alvarez-Silva C, "Trans-ethnic gut microbiota signatures of type 2 diabetes in Denmark and India", Genome Med, 13, pp.37~ (2021)
46. Wu H, "Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug", Nat Med, 23, pp.850~858 (2017)
47. Zhou ZY, "Metformin exerts glucose-lowering action in high-fat fed mice via attenuating endotoxemia and enhancing insulin signaling", Acta Pharmacol Sin, 37, pp.1063~1075 (2016)
48. Ahmadi S, "Metformin reduces aging-related leaky gut and improves cognitive function by beneficially modulating gut microbiome", goblet cell, J Gerontol A Biol Sci Med Sci, pp.2020, 75[DOI]
49. Sun L, "Gut microbiota and intestinal FXR mediate the clinical benefits of metformin", Nat Med, 24, pp.1919~1929 (2018)
50. De Vadder F, "Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits", Cell, 156, pp.84~96 (2014)
51. Wanchaitanawong W, "Repurposing metformin as a potential treatment for inflammatory bowel disease : evidence from cell to the clinic", Int Immunopharmacol, 112, pp.109230~ (2022)
52. Ke H, "Metformin exerts anti-inflammatory and mucus barrier protective effects by enriching Akkermansia muciniphila in mice with ulcerative colitis", Front Pharmacol, 12, pp.726707~ (2021)
53. Liu Z, "Metformin affects gut microbiota composition and diversity associated with amelioration of dextran sulfate sodium-induced colitis in mice", Front Pharmacol, 12, pp.640347~ (2021)
54. Misirkic Marjanovic MS, "Dual anticancer role of metformin : an old drug regulating AMPK dependent", independent pathways in metabolic, oncogenic, Am J Cancer Res, pp.2021, 11[DOI]
55. Hui F, "Role of metformin in overweight and obese people without diabetes : a systematic review and network meta-analysis", Eur J Clin Pharmacol, 75, pp.437~450 (2019)
56. Nojima I, "Metformin and its immune-mediated effects in various diseases", Int J Mol Sci, 24, pp.755~ (2023)
57. Du Y, "Metformin in therapeutic applications in human diseases : its mechanism of action and clinical study", Mol Biomed, 3, pp.41~ (2022)
58. Shafqat A, "Emerging role of neutrophil extracellular traps in the complications of diabetes mellitus", Front Med(Lausanne), 9, pp.995993~ (2022)
59. Menegazzo L, "The antidiabetic drug metformin blunts NETosis in vitro and reduces circulating NETosis biomarkers in vivo", Acta Diabetol, 55, pp.593~601 (2018)
60. Rohm TV, "Inflammation in obesity, diabetes, and related disorders", Immunity, 55, pp.31~55 (2022)
61. Zhang P, "Association of metformin use with cancer incidence and mortality : a meta-analysis", Cancer Epidemiol, 37, pp.207~218 (2013)
62. Goodwin PJ, "Effect of metformin vs placebo on invasive disease-free survival in patients with breast cancer : the MA. 32 randomized clinical trial", JAMA, 327, pp.1963~1973 (2022)
63. Kim HS, "The addition of metformin to systemic anticancer therapy in advanced or metastatic cancers : a meta-analysis of randomized controlled trials", Int J Med Sci, 17, pp.2551~2560 (2020)
64. Chen Y, "Diabetes medications and cancer risk associations : a systematic review and meta-analysis of evidence over the past 10 years", Sci Rep, 13, pp.11844~ (2023)
65. Melton LJ 3rd, "Fracture risk in type 2 diabetes : update of a population-based study", J Bone Miner Res, 23, pp.1334~1342 (2008)
66. Lambova SN, "Pleiotropic effects of metformin in osteoarthritis", Life(Basel), 13, pp.437~ (2023)
67. Crouse AB, "Metformin use is associated with reduced mortality in a diverse population with COVID-19 and diabetes", Front Endocrinol(Lausanne), 11, pp.600439~ (2021)
68. Lukito AA, "The effect of metformin consumption on mortality in hospitalized COVID-19 patients : a systematic review and meta-analysis", Diabetes Metab Syndr, 14, pp.2177~2183 (2020)

관련 논문AI추천